US Headache Study
Frequency of Any Headache Occurence over the Pre-emptive Phase 7-Day Treatment Period
Patients in the placebo group had moderate or severe headaches on 237 days (20.3% of the possible days) during the study, compared with 262 (21.8%) in the acetaminophen group (NS). On the first day, 41.2% of the subjects receiving placebo developed headache after the first DAC administration, compared to 48.8% in the acetaminophen group. On the last day (day 7) these numbers were 17.1% and 18.6% (p 0.001, 2 for trends). Participants receiving placebo experienced 1,167 headaches over the study, compared to 1,201 in the acetaminophen group (NS). No significant differences were observed between groups in any of the secondary endpoints (data not shown).
Frequency of Any Headache Occurence over the Pre-emptive Phase 7-Day Treatment Period
